hairallah CG, Wild SR, et al. Fabry 
disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol 14: 298302. Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, et al. Alphagalactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111: 629632. Park JL, Whitesall SE, D’Alecy LG, Shu L, Shayman JA Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol 35: 11561163. Shu L, Park JL, Byun J, Pennathur S, Kollmeyer J, et al. Decreased Nitric Oxide Bioavailability in a Mouse Model of Fabry Disease. J Am Soc Nephrol. Rozenfeld PA, Fritz M, Blanco P, Gonzalez P, Rinaldi GJ Myocardial alterations in the murine model of fabry disease can be reversed by enzyme replacement therapy. Canadian J Cardiol 27: 339345. 27. Bichara M, Attmane-Elakeb A, Brown 10595516” D, Essig M, Karim Z, et al. Exploring the role of galectin 3 in kidney function: a genetic approach. Glycobiology 16: 3645. 28. Sainte-Marie Y, Nguyen Dinh Cat A, Perrier R, Mangin L, Soukaseum C, et al. Conditional glucocorticoid receptor expression in the heart induces atrioventricular block. FASEB J 21: 31333141. 29. Parlakian A, Charvet C, Escoubet B, Mericskay M, Molkentin JD, et al. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation 112: 29302939. 30. Whittaker P, Kloner RA, Boughner DR, Pickering JG Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol 89: 397410. 31. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111: 30253033. 32. Schellings MW, Pinto YM, Heymans S Matricellular proteins in the heart: possible role during stress and remodeling. Indirubin-3′-oxime Cardiovas Res 64: 2431. 33. Mallon AM, Blake A, Hancock JM EuroPhenome and EMPReSS: online mouse phenotyping resource. Nucleic Acids Res 36: D715718. 34. Guo X, Kono Y, Mattrey R, Kassab GS Morphometry and strain distribution of the C57BL/6 mouse aorta. Am J Physiol Heart Circ Physiol 283: H18291837. 35. Shu L, Murphy HS, Cooling L, Shayman JA An in vitro model of Fabry disease. J Am Soc Nephrol 16: 26362645. 36. Barbey F, Qanadli SD, Juli C, Brakch N, Palacek T, et al. Aortic remodelling in Fabry disease. Eur Heart J 31: 347353. 37. Sadick N, Thomas L Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study. Heart Lung Circ 16: 200206. 38. Chimenti C, Hamdani N, Boontje NM, DeCobelli F, Esposito A, et al. Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol 172: 14821490. 39. Toro R, Perez-Isla L, Doxastaquis G, Barba MA, Gallego AR, et al. Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 132: 3844. 40. Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am 18353306” J Cardiol 96: 842846. 41. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, et al. Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey. J Med Genet 46: 548552. 42. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P Life expectancy and cause of death in males and females with Fabr